Italian journal of dermatology and venereology · 2026
Doxycycline postexposure prophylaxis: a cross-sectional survey on knowledge, attitudes and prescribing practices among Italian dermatologists of sexually transmitted infection centers.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Donà Maria Gabriella, Zaccarelli Mauro, Giuliani Eugenia, Colli Claudia, Atzori Laura, Gaspari Valeria, Ramoni Stefano, Pisano Luigi, Cariello Francesco, Pugliese Antonio, Ciccarese Giulia, Balestri Riccardo, Latini Alessandra, Doxy-DERM Group
Аннотация
BACKGROUND: Postexposure prophylaxis with doxycycline (Doxy-PEP) significantly reduces incidence of certain bacterial STIs in men who have sex with men (MSM) and individuals with recurrent STIs. We assessed knowledge, attitudes, and clinical experience regarding Doxy-PEP of dermatologists specialized in STI prevention, diagnosis, and treatment in Italy.
METHODS: A cross-sectional survey was conducted in March 2025 using a questionnaire to investigate knowledge of Doxy-PEP prescribing protocols and patient eligibility, perceptions of its efficacy against several STIs, personal experience in Doxy-PEP prescription and drawbacks, opinions on its future use.
RESULTS: Thirty-six dermatologists participated. All knew about Doxy-PEP. The population most frequently considered eligible for Doxy-PEP was represented by MSM (69.4%). Respondents would prescribe Doxy-PEP after recent exposure (<72 hours) to chlamydia (58.3%), syphilis (50.0%), gonorrhea (25.0%), or multiple partnership (55.6%). Chemsex was indicated as the main risky behavior worth prescribing Doxy-PEP (69.4%). Approximately half of the respondents considered Doxy-PEP effective against chlamydia (47.2%), whereas only 14.3% and 2.8% were convinced of its efficacy against syphilis and gonorrhea, respectively. Only 19.4% of the respondents had prescribed Doxy-PEP, with no adverse events reported. Doxy-PEP failure was observed by 36.1% of the dermatologists. The main concerns included Neisseria gonorrhoeae resistance (91.7%), methicillin-resistant Staphylococcus aureus (MRSA) selection (91.7%), and microbiota alterations (86.1%). A progressive increase in Doxy-PEP use is anticipated, driven by patient demand, community influences, and international guidelines.
CONCLUSIONS: Dermatologists of Italian STI centers demonstrate appropriate awareness of Doxy-PEP but maintain cautious attitudes toward efficacy and show a substantial concern about antibiotic resistance.
METHODS: A cross-sectional survey was conducted in March 2025 using a questionnaire to investigate knowledge of Doxy-PEP prescribing protocols and patient eligibility, perceptions of its efficacy against several STIs, personal experience in Doxy-PEP prescription and drawbacks, opinions on its future use.
RESULTS: Thirty-six dermatologists participated. All knew about Doxy-PEP. The population most frequently considered eligible for Doxy-PEP was represented by MSM (69.4%). Respondents would prescribe Doxy-PEP after recent exposure (<72 hours) to chlamydia (58.3%), syphilis (50.0%), gonorrhea (25.0%), or multiple partnership (55.6%). Chemsex was indicated as the main risky behavior worth prescribing Doxy-PEP (69.4%). Approximately half of the respondents considered Doxy-PEP effective against chlamydia (47.2%), whereas only 14.3% and 2.8% were convinced of its efficacy against syphilis and gonorrhea, respectively. Only 19.4% of the respondents had prescribed Doxy-PEP, with no adverse events reported. Doxy-PEP failure was observed by 36.1% of the dermatologists. The main concerns included Neisseria gonorrhoeae resistance (91.7%), methicillin-resistant Staphylococcus aureus (MRSA) selection (91.7%), and microbiota alterations (86.1%). A progressive increase in Doxy-PEP use is anticipated, driven by patient demand, community influences, and international guidelines.
CONCLUSIONS: Dermatologists of Italian STI centers demonstrate appropriate awareness of Doxy-PEP but maintain cautious attitudes toward efficacy and show a substantial concern about antibiotic resistance.